How is real-world data affecting how bispecifics are administered?

There's still a lot to learn about therapies after they are FDA-approved, even from bispecific antibody therapy. 

Real-world data, brought to the myeloma community by patients just like you, tells us more about the treatment, its side effects, administration, and the impact on quality of life better than a clinical trial can. 

As time passes, doctors will adjust dosages, learn how to manage side effects, or understand more about patient responses as more patients are being prescribed the therapy. 

Make educated decisions with your doctor about proper adjustments to your treatment if necessary.

Here are some things that experts are learning and anticipated changes regarding bispecific antibody treatment for myeloma due to real-world data.  

• Hospital stay duration: Some facilities are keeping their patients for 7 days when scheduling the step-up dosing instead of the full 9 days recommended by the package insert.
• Dosing could also change depending on patient tolerance and needs. 
• Bispecifics may not always require administration in the hospital. Specialists expect it could become an outpatient administration once more data and better prophylactic approaches and symptom monitoring support that. 
• Bispecifics won’t be given until progression- but rather have an adjusted duration of therapy by monitoring the level of response (such as stringent complete response or minimal residual disease rates). 

Real-world data will eventually tell us more somber things and long-term results as well, such as any risks of developing secondary cancers due to bispecific antibody therapy use.